Aptus Capital Advisors, LLC United Therapeutics Corp Transaction History

Aptus Capital Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$205.95 - $280.43 $138,192 - $188,168	-671 Reduced 21.74%	2,415 $671,000
Q3 2022 Nov 02, 2022	BUY	$203.3 - $244.17 $627,383 - $753,508	3,086 New	3,086 $646,000
Q4 2019 Feb 10, 2020	SELL	$78.31 - $95.34 $1.32 Million - $1.61 Million	-16,879 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$74.85 - $85.99 $154,116 - $177,053	2,059 Added 13.89%	16,879 $1.35 Million
Q2 2019 Aug 13, 2019	BUY	$76.06 - $120.81 $27,609 - $43,854	363 Added 2.51%	14,820 $1.16 Million
Q1 2019 May 15, 2019	BUY	$107.15 - $126.84 $137,366 - $162,608	1,282 Added 9.73%	14,457 $1.7 Million
Q4 2018 Feb 12, 2019	BUY	$101.4 - $128.73 $1.34 Million - $1.7 Million	13,175 New	13,175 $1.43 Million

676

42.1M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.9B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Aptus Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Aptus Capital Advisors, LLC with notifications on news.